Altheia: Proliferating PD-L1
How Altheia is boosting PD-L1 expression to treat autoimmune diseases
Rather than blocking PD-L1 to treat cancer, Altheia Science s.r.l. is increasing expression of PD-L1 via a cell therapy to promote immune tolerance in autoimmune diseases, starting with Type I diabetes and multiple sclerosis.
Altheia was founded by tech transfer company AurorA-TT in 2017 with rights to IP from Boston Children’s Hospital covering PD-L1-expressing hematopoietic stem cells (HSCs).